Multidrug resistance is one of the most serious problems in the treatment of epilepsy that is likely to have a complex genetic and acquired basis. Various experimental data support the hypothesis that over-expression of antiepileptic drug (AED) transporters may play a pivotal role in drug resistance. However, key questions concerning their functionality remain unanswered. The idea that P-glycoprotein, encoded by the ABCB1 gene, might mediate at least part of the drug resistance was met with both enthusiasm and skepticism. As in oncology, initial optimism has been clouded subsequently by confl icting results. The fi rst study reporting a positive association between genetic variation in the P-glycoprotein and multidrug-resistant epilepsy was published in 2003. Since then, several other genetic association studies have attempted to verify this result. However, taken overall, the role of P-glycoprotein in drug resistance in epilepsy still remains uncertain. We intend to critically review the inherent problems associated with epilepsy pharmacogenetic studies in general and with ABCB1 polymorphisms studies in particular. The lessons learnt from the ABCB1 studies can help us to guide future association genetics studies to investigate AED resistance, and thereby taking us closer to the cherished dream of personalized AED therapy.
Introduction
Epilepsy is the most prevalent chronic neurological S13 An overview of antiepileptic drug resistance Resistance to AED is considered as a complex phenomenon that may involve many mechanisms, none of which is well understood. [8, 9] Any hypothesis (es) concerning the mechanisms of pharmacoresistance should be consistent with the following facts about this condition: [4, 10] fi rst, resistance to AED occurs across a wide range of seizure types, etiologies and a variety of AEDs. Second, the majority of patients with drugresistant epilepsies are unresponsive right from the beginning of AED treatment, indicating that acquired factors are unlikely to explain this phenomenon. Third, the majority of patients who are unresponsive to the fi rst or second AED used continue to remain unresponsive to all AEDs, including the newer ones, and even to multiple AED combinations, indicating that they are multidrug resistant right from the beginning. Fourth, in patients with drug-resistant epilepsies, therapeutic serum AED monitoring and optimizing the dosages seldom results in better seizure control, indicating that decreased AED absorption or increased metabolism is unlikely to be a major cause of AED failure in the majority.
Currently, two major hypotheses have been put forward to explain AED resistance in epilepsy. [8, 9] The Transporter hypothesis surmises that region-specifi c expression or function of mutidrug effl ux transporters at the blood-brain barrier [ Figure 1 ] is enhanced, leading to impaired access of AEDs to the central nervous system sites. [11] Consequently, drug concentrations are too low to induce antiepileptic effects at brain sites initiating seizures. The Target hypothesis contends that changes in the drug targets (receptors) themselves result in reduced AED sensitivity. [12] Because drug resistance often occurs in a patient to multiple AEDs, if not to all the currently available AEDs simultaneously, the multidrug transporter hypothesis is considered in preference to alterations at specifi c drug receptor sites to explain the phenomenon of multi-AED resistance.
However, the transporter and target hypotheses are not mutually exclusive; they may complement each other in the pathogenesis of AED resistance.
The role of P-glycoprotein in antiepileptic drug resistance
Numerous multidrug transport proteins are known, and share the general ability to transport a variety of drugs, which often have disparate chemical structures, against concentration gradients, reducing the desired effects of those drugs. P-glycoprotein (permeability glycoprotein, abbreviated as P-gp) is the archetypal example of such a protein, and has been proposed as a mediator of drug resistance and in disparate human conditions, including various cancers, infections such as malaria, infl ammatory conditions such as rheumatoid arthritis and Crohn's disease, and disorders of the central nervous system. P-glycoprotein is a well-characterized ATP-binding cassette (ABC) transporter of the MDR/TAP subfamily and is coded by the ABCB1 (ATP-binding cassette subfamily B member 1) gene located at the chromosome 7q21.12. [13] P-gp is extensively distributed and expressed in the intestinal epithelium, hepatocytes, renal proximal tubular cells, adrenal gland and capillary endothelial cells comprising the blood-brain and blood-testis barrier. It is an ATP-dependent effl ux pump, with a broad substrate specifi city, and functions as the major drug-effl ux transporter at the blood-brain barrier [ Figure 1 ]. Most AEDs, being Das, et al.: Pharmacoresistance in epilepsy and the ABCB1 gene Figure 1 : The structure of P-glycoprotein: The structure of P-glycoprotein that transports drugs out of the cell, which is a process that requires the presence of two ATP-binding domains. These domains are a defi ning characteristic of this family of ATP-binding cassette (ABC) transporters. The exact mechanism of drug effl ux is not well understood, but might involve either direct transport out of the cytoplasm or redistribution of the drug as it transverses the plasma membrane. AEDs, anti-epileptic drugs S14 planar lipophilic agents, are thus substrates for the ABCB1 transporter. Because most AEDs are only weak substrates for P-gp, the basal (constitutive) expression of P-gp at the blood-brain barrier is unlikely to restrict brain penetration of AEDs to any clinically important extent. [14] However, intrinsic or acquired over-expression of P-gp in the blood-brain barrier may critically limit the drug penetration into the brain, leading to resistance against all AEDs that are substrates of P-gp. [4, 11, 14] To prove the plausibility of a mechanism responsible for drug resistance, the following criteria have been proposed, which remain a good starting point for addressing the issue: [15] (i) resistance mechanisms must be detectable in epileptogenic brain tissue, (ii) resistance mechanisms must have appropriate functionality, (iii) they must be active in drug resistance, and (iv) overcoming the mechanisms should ameliorate drug resistance. Currently, there is extensive evidence that fulfi lls the above criteria and supports the role of increased expression of P-gp and other drugefflux transporters in AED-resistance. [4, 14] In rodent models of temporal lobe epilepsy, the increased P-gp expression in the hippocampus and the parahippocampal regions was associated with signifi cantly decreased concentrations of AEDs in these regions. [16, 17] In patients with oxcarbazepine-resistant epilepsy, the brain tissue expression of ABCB1 mRNA was found to be inversely correlated with the brain levels of 10,11-dihydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide (10-OHCBZ), the active metabolite of oxcarbazepine, indicating that P-gp may play a role in the resistance to oxcarbazepine by causing insuffi cient concentrations of its active metabolite at neuronal targets. [18] The expression of ABCB1/MDR1 in the epileptic foci of drugresistant epilepsy patients was shown to be elevated 10-folds, indicating its signifi cant role in epilepsy. [19] Elevated levels of MDR1 and multidrug-associated protein (ABCC1/MRP1) have also been associated with pathologies associated with drug refractoriness, such as in tuberous sclerosis, and also in epileptic tissue surrounding dysembryoplastic neuroepithelial tumors, focal cortical dysplasia and hippocampal sclerosis. The adjacent nonepileptic tissue from the same patients did not show elevated expression of the transporter, indicating reduced drug availability to the epileptic foci. [20] Using an in vitro blood-brain barrier model with human capillary endothelial cells from either normal brain or drug-resistant epileptic brain, Cucullo et al. [21] recently reported a dramatically reduced permeability of phenytoin across the in vitro blood-brain barrier formed from endothelial cells of patients with refractory epilepsy, which could be partially counteracted by the selective P-gp inhibitor, tariquidar. [21] In line with this observation, the decrease in brain concentrations and resistance to AEDs, such as phenytoin or phenobarbital, associated with P-gp over-expression in rodent models could be counteracted by tariquidar in vivo, suggesting a causal association between P-gp overexpression and AED resistance. [17, 22, 23] Such P-gp over-expression can result from the effects of disease or drug treatment on P-gp expression or from ABCB1 polymorphisms, and might explain the clinical observation that patients with refractory epilepsy are usually resistant to a broad range of AEDs with different mechanisms of action. [4] ABCB1 polymorphism in antiepileptic drugresistance
The human ABCB1 gene is which results in amino acid exchanges (Ala893Ser or Ala893Thr). [25] However, a recent study showed that the synonymous C3435T SNP in exon 27, although not resulting in amino acid changes itself, is not "silent,"
but results in P-gp with altered drug and inhibitor interactions. [26] For the three SNPs described above, ethnic differences have been reported with allele frequencies varying from 45 to 55% in Whites and 5 to 10% in African
Americans. [27] The extent of the genotypic effects of these polymorphisms on drug refractoriness in epilepsy has attracted renewed attention.
Conflicting evidences for the role of ABCB1 polymorphism in antiepileptic drug resistance
In 2003, Siddiqui et al. [28] reported the C3435T polymorphism in the ABCB1 gene as being associated with resistance to multiple AEDs, and leading to the suggestion, for the fi rst time, that drug resistance in epilepsy might be genetically determined. [28] The study was a retrospective case-control study that compared the frequencies of the ABCB1 C3435T variant in 115 AED responders, with 200 AED-resistant patients and 200 nonepileptic controls. Patients with multidrugresistant epilepsy were signifi cantly more likely to be homozygous for the C allele than the T allele. Because the CC genotype has been associated with increased expression of intestinal P-gp, [24] the data of Siddiqui et al. [28] suggested that the CC genotype may be associated with increased expression and functionality of P-gp also at the blood-brain barrier, leading to reduced AED levels at their brain targets. In a follow-up study by the same group, the association of AED resistance with the 3435C>T polymorphism was confi rmed in a larger group of patients, and intronic sites that are strongly associated with the 3435C>T polymorphism were identifi ed. [29] This study initiated several subsequent genetic association studies, using a candidate gene approach with either one SNP or a haplotype [ Table 1 ]. Six of these studies, genotyping either ABCB1 3435 or the common haplotype
confi rmed the association between the 3435 SNP or the three-SNP haplotype (containing the 3435 SNP) and
AED-resistant epilepsy. However, in two studies in non-Caucasian subjects, the association was in the reverse direction compared with studies in Caucasian subjects, in that patients with drug-resistant epilepsy were more likely to have the TT genotype compared with those with drug-responsive epilepsy, [31, 32] 
Lack of replication: The causes and their clinical implications
All the studies done so far in ABCB1 polymorphisms and AED-resistance in epilepsy are candidate genebased genetic association studies, either SNP based or haplotype based, with their inherent limitations. Risch and Merikangas [46] identifi ed SNPs as putative genetic AEDs that might not be P-gp substrates. [50] In this review, we have limited ourselves to the issues that are more important from the clinical perspective. The clinician should be aware of these issues for a better understanding of the genetic association studies and to make valuable contributions in the future studies.
Phenotypic heterogeneity
Epilepsy is a heterogeneous condition. Different [28] defined drug resistance as the occurrence of at least four seizures over the year before recruitment with trials of more than three appropriate AEDs at maximal tolerated doses, which were established on the basis of the occurrence of clinical side-effects at supramaximal doses. Where it was possible, only the recognized, more specifi c drugs for a syndrome were considered appropriate -e.g., failure of a case of idiopathic generalized epilepsy to respond to carbamazepine was not considered a failure for the purposes of the study. However, only in one of the subsequent studies [36] was the above defi nition for drug resistance replicated. There is no consistent clinical defi nition of multidrug resistance in epilepsy, and agreement among the different defi nitions is strong but imperfect. [51] This has resulted in diverse criteria used by different researchers, or even a lack of explicit criteria in some cases, rendering it diffi cult to compare the fi ndings across studies. The recent consensus defi nition of drug resistance, as provided by the Task Force appointed by the International League Against Epilepsy (ILAE), is a much needed step to address this issue. [52] However, it should be emphasized that given the paucity of highquality data on the long-term prognosis of epilepsy, the proposed defi nition should not be regarded as a foregone conclusion, but is intended to represent a consensus opinion that needs to be tested in rigorous prospective studies and refi ned as new evidence emerges.
As patients with multidrug resistance will typically not respond to a variety of AEDs with differing modes of action, it has been suggested that the biological mechanism underlying multidrug resistance is nonspecifi c, i.e. it is not unique to any one particular AED or subset of AEDs. However, this notion has been recently challenged by the elegant study done by Kimchi-Sarfaty et al., [26] who showed that a synonymous SNP (i.e., a so-called silent mutation) at the 3435 locus of the ABCB1 gene alters P-gp conformation and its interaction with drug substrates and inhibitors, while expression levels of mRNA and protein remain the same. The synonymous mutation apparently affects the timing of cotranslational folding of P-gp. Hence, the transport function of P-gp not only depends on genotype at specifi ed loci within ABCB1 but also, critically, that differences in transport function are exaggerated when the transcription machinery is put under stress. Thus, the genotype dependence of transport function is exaggerated under the stimulated state in comparison with the basal or repressed state. In specifi c experimental models, both seizures and AED treatment can induce ABCB1 expression, and would therefore be expected to amplify any ABCB1 genotype effect on P-gp quantity and function. [11] Therefore, if phenotypes are not matched between studies, e.g. if one study focuses on a cohort with a more severe "drug-resistant" phenotype (in comparison with a control cohort) while another study examines a less-severe "drug-resistant" cohort, there is good reason to believe that genotypedependent differences should be expected between these studies. Thus, a stratifi cation bias would already exist and misdirect the results toward nonreplication from the outset. [53] This point duly emphasizes the importance of matching phenotypes across studies or cohorts.
Are all antiepileptics transported by P-gp?
Fifteen of the 18 genetic association studies summarized in Tables 1 and 2 included patients on treatment with various AEDs, for several of which it is either not yet known whether they are transported by P-gp or which do not seem to be transported by P-gp (e.g., valproate). [54] Only three studies included patients on a single AED, either phenytoin or carbamazepine. [32, 34, 41] For carbamazepine, data on transport by P-gp are, at best, equivocal, [55, 56] whereas there is ample evidence that phenytoin is transported by P-gp, [57] which could explain the recent fi nding of Ebid et al. [34] that the CC genotype of ABCB1 3435 is signifi cantly associated with phenytoin resistance in patients with epilepsy. It should be noted that the results of the Ebid et al. [34] study differed substantially from other similar studies, in that a highly signifi cant association between 3435CC and resistance to phenytoin was found despite a smaller sample size (100 patients only compared with >300 in most other studies). A number of other concerns exist about the clarity of the reports and the study designs. Hence, the studies containing patients who use a set of AEDs different from another patient cohort are not directly comparable. It is also important to remember the discussion made previously, in light of the fi ndings by Kimchi-Sarfaty et al., [26] that P-gp functionality will also depend on the AEDs used, making the comparison much more complicated. As the multidrug-resistant patients will continue to use many AEDs, often differing along the course of illness, it would be exceedingly diffi cult, if not impossible, to control this important confounding factor.
Is P-gp the only antiepileptic exporter?
Almost all previous studies on gene variation that might affect AED distribution have dealt with polymorphisms in the ABCB1 gene that encodes P-gp. However, there are polymorphisms in other drug effl ux transporters, such as members of the MRP family, which may affect the distribution of AEDs [57] and need further investigation.
One of these transporters, RLIP76, has been suggested to be involved in AED resistance by transporting both carbamazepine and phenytoin at the blood-brain barrier, [58] but a recent genetic analysis of RLIP76 genotypic and haplotypic frequencies in 783 patients with epilepsy and 359 healthy controls showed no signifi cant differences for genotypic frequencies between drugresistant and drug-responsive patients. [59] Is ABCB1 associated with epilepsy per se?
Several of the many association studies on ABCB1
in epilepsy not only analyzed drug-responsive and -nonresponsive epilepsy patients but also analyzed the ABCB1 genotypes in control subjects without epilepsy, and found that in fact ABCB1 genotypes were associated with the disease per se rather than specifi cally with drug responsiveness. [14] In our study from patients with south Indian ancestry (unpublished), we also had similar fi ndings but with a different SNP from the ABCB1 gene. This suggests that the reported association studies on this gene may be looking simply at the random segregation of epilepsy patients into the two drug-response groups, such that in half of the studies an association was found and in the other half of the studies the results were negative.
The question of power
The most fundamental problem with current efforts is the relatively low sample size in most studies, resulting in limited power to either detect or to rule out a defi nitive association. Few investigators working on epilepsy genetics have large cohorts for any particular type of epilepsy, including the recent and previous efforts. It does not appear that, in the near future, individual investigators will be able to increase their own sample sizes to levels suffi cient to carry out highly powered association studies within the various forms of epilepsy. [60] The following pertinent lessons could be learned from the lack of consistency in the results from different studies on ABCB1 polymorphisms on drug resistance: fi rst, the fi eld must concentrate more seriously on efforts to determine which polymorphisms have real effects, as opposed to always racing to publish a new association. False-positives are clearly exacerbated by the publication of multiple small studies and the practice of data exploration to identify subgroups that show associations. This fact must be recognized and addressed. Second, and most fundamental, it is critical for different research groups to increase substantially the size of their patient cohorts. Given that this will take time, we feel that in the short term, groups should combine their epilepsy samples and attempt to replicate one another's results in a population of similar ethnicity before publication. Although collaboration to such a level could be viewed as controversial from a scientifi c point of view, we feel that the trade-off is justifi ed. It is only with such steps that the epilepsy community, like other disease subspecialties, will be able to arrive at a reasonable false to true discovery ratio in reported associations.
Genome-wide association studies: Is it the future?
The techniques of a candidate gene-based approach are limited because our current understanding of gene function is too limited to allow us to predict which genes are involved with a particular trait. The genome wide association studies (GWAS), which agnostically evaluate the patterns of association between variation in the genome and carefully defined disease phenotypes, present an enhanced experimental framework to rapidly identify novel pathogenic mechanisms and to confi rm a role for previously known mechanisms. [61] The completion of the human genome sequence in 2005 and the provision of an initial catalogue of human genetic variation and a haplotype map (known as the HapMap), together with rapid improvements in genotyping technology and analysis, have permitted genome wide association studies to be undertaken in a large number of samples. [62] In the fi rst and current implementation of this approach, the great majority of genetic variants with population frequencies of 5% or more could be tested directly or indirectly for association with disease risk or quantitative traits thus providing a potential path to gene discovery for polygenic diseases and traits. During the past couple of years, GWAS have identifi ed more than 250 genetic loci, in which common genetic variants occur that are reproducibly associated with polygenic traits. [63] This explosion represents one of the most prolifi c periods of discovery in human genetics. However, the problems of phenotypic assertion and population stratifi cation will also continue to plague this technique, exaggerated by the inherent complicated issue of multiple testing in GWAS. GWAS simply escalates the problem of multiple testing by orders of magnitude. Because SNPbased GWAS test hundreds of thousands of SNPs per subject, a signifi cant association requires a very low probability value. [64] The Wellcome Trust Case Control Consortium used P < 5x10 -7 as the cut-off for genome wide signifi cance. Others have chosen to prespecify genome wide signifi cance with greater stringency at P < 5x10 -8 , corresponding to the 5% signifi cance level adjusting for the number of independent tests estimated in HapMap for individuals of European ancestry. [64] This leads to the requirement of a large sample size, which is already a problem in epilepsy genetics. Altshuler and Daly [65] calculated sample sizes required to have 90% power to repeat the fi ndings of previous GWAS at a P-value threshold of 10 -8 . To put things in perspective, the most strongly associated SNPs would individually require 2,500 cases and controls; most would need 10,000-20,000. In many of the diseases studied so far, there are multiple SNP associations such that, although 20,000 cases may be required to guarantee identifying a given SNP, smaller studies may still identify a proportion of SNP associations. Recent large GWAS have provided empirical justifi cation for stringent P-values. A recently reported, two-stage GWAS in breast cancer included over 25,000 cases and 25,000 controls. [66] In the fi rst stage, 4,000 cases and controls were genotyped. The most signifi cant SNPs were retested in an independent sample of 21,000 cases and controls. This large study offers insight into the relationship between P-values in stage 1 and confi rmation in stage 2. No SNPs with a P-value less stringent than 10 -6 survived stage 2 and P-values between 10 -7 and 10 -8 had some chance of failure. Hence, while it has been argued that P-values as high as 10 -5 may be suffi cient in stage 1, there is increasing consensus that P-values of 10 -8 are required.
There is what might be called large numbers of imperatives when it comes to GWAS of a complex disorder like epilepsy. It is unlikely that any single study, even a multicenter study, will ever achieve the sample size necessary to yield a credible result. An uncommon level of worldwide collaboration must emerge, which has already started in some other neurological disorders. [67] 
Conclusions
The role of genetic variation in drug effl ux transporter genes for AED distribution and effi cacy remains uncertain at present. Progress in the pharmacogenomics of multidrug resistance in epilepsy has been slow. However, a number of lessons can be learnt from the studies conducted. A clear defi nition of the multidrug-resistant phenotype is fundamental in order to ensure consistency among studies and to ensure that patients classifi ed as multidrug resistant are indeed unlikely to respond to any AED. Heterogeneity of AED treatment among patients also needs to be considered, e.g. if overexpression of P-gp is a factor in multidrug resistance, then a different mechanism would be required to explain nonresponse to an AED that is not thought to be a substrate for P-gp (e.g., vigabatrin). Functional studies must support association genetics to establish biological plausibility. Investigating multidrug resistance for certain epilepsy subtypes or AED combinations will be a diffi cult task. Association genetics requires large cohort sizes, and further refi ning the multidrug-resistant phenotype or inclusion criteria will Das, et al.: Pharmacoresistance in epilepsy and the ABCB1 gene S20 make it harder to recruit suffi cient patients. GWAS will require particularly large cohorts given the number of polymorphisms examined and the number of likely falsepositive associations. Collaboration between centers will prove increasingly important not only to increase cohort sizes but also to replicate genetic associations.
